Even short-term hormone replacement therapy use associated with increased ovarian cancer risk
the ONA take:
A meta-analysis of 52 epidemiological studies on hormone replacement therapy (HRT) and ovarian cancer indicate that HRT use, even for less than 5 years, increased women’s risks of developing ovarian cancer. The reviewed studies represent virtually all the epidemiological evidence ever collected on HRT use and ovarian cancer.
The international Collaborative Group on Epidemiological Studies of Ovarian Cancer, involving more than 100 researchers worldwide organized by the University of Oxford, in the United Kingdom, analyzed individual participant data from 21,488 women with ovarian cancer, almost all from North America, Europe, and Australia.
Their findings indicate that women who use HRT for just a few years have an approximately 40% higher risk of developing ovarian cancer than women who have never taken HRT.
This increase in risk was seen in only the two most common types (serious and endometrioid ovarian cancers), and not in mucinous and clear cell ovarian cancers, which are less common types. Study co-author Professor Dame Valerie Beral, from the University of Oxford, suggests that the definite increase in risk of ovarian cancer has implications for the current efforts to revise guidelines for HRT use.
Women who use hormone replacement therapy for just a few years have an approximately 40% higher risk of developing ovarian cancer.
- Study Identifies Factors Associated With Hearing Loss in Polycythemia Vera
- Ezh2 Inhibitors May Offer Cure for Chronic Myelogenous Leukemia
- Ruxolitinib: A Targeted Treatment Option for Patients with Polycythemia Vera
- Incontinence Affects QOL for Survivors of Gynecologic Cancers
- Robotic Surgery Provides Good Outcomes and Survival in Oropharyngeal Cancer
- Overall Benefits of Vaporized Nicotine Products Outweigh Harms, Says International Panel of Experts
- Sugar and Cancer: Mitigating the Affects of Diet on Cancer
- Nurse Residency Programs Can Impact Oncology Nursing Practice, Outcomes
- Tumor Markers (Fact Sheet)
- Implementing a Distress Screening Process for Cancer Patients
- SBRT Improves Overall and Disease-Specific Survival in Stage I NSCLC
- Patients Receiving RT in APBI Facilities Despite Eligibility for Observation
- Prolonged Imatinib Therapy Improves Likelihood of Deeper Molecular Response
- ASCO, ASTRO Issue Guideline Update for Postmastectomy RT
- Study Assesses Efficacy of Ramucirumab in HCC by Child-Pugh Score
Sign Up for Free e-newsletters
Regimen and Drug Listings
GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION
|Head and Neck Cancer||Regimens||Drugs|